AngioPredict Coordinator secures new research funding to develop predictive biomarkers for colorectal cancer

print version


Angiopredict Coordinator Dr Annette Byrne (RCSI) has received funding of €629,241 from Science Foundation Ireland (SFI) for a new research project entitled "ColoForetell: A Xenopatient Discovery Platform for the integrated Systems based Identification of Predictive Biomarkers for Targeted Therapies in Metastatic Colorectal Cancer".

Dr Byrne's ColoForetell project was included on the list of new grants announced on 8 July 2014 by the Irish Minister for Research and Innovation, Mr Se├ín Sherlock, T.D. The new research is related to Angiopredict, given its focus on the development of predictive biomarkers for the tyrosine kinase inhibitor drug Regorafenib [Stivarga], which is approved for the treatment of metastatic colorecal cancer. Several Angiopredict partners including Prof Jochen Prehn, Dr Bryan Hennessy and Prof Diether Lambrechts (Angiopredict Scientific Co-ordinator) worked with Dr Byrne to secure this new source of funding. The project is a collaboration with Bayer Healthcare and supports a new interaction with Prof Livio Trusolino at the University of Turin, Italy. Prof Trusolino is a World Leader in developing patient derived xenograft models (xenopatients) for application in colorectal cancer translational research. 

A link to the announcement on the SFI website is provided below:€23-million-in-sfi-funding-to-ireland's-most-promising-young-scientific-talent.html